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The IASLC Lung Cancer Staging Project: “The Nodal Zone”
Katherine M. W. Pisters, MD, and Gail Darling, MD
The paper by Rusch et al.1 represents a Herculean effort by the staging committee of theInternational Association for the Study of Lung Cancer (IASLC) to determine whether
the current nodal descriptors for non-small cell lung cancer2 should be maintained or
revised. A retrospective international lung cancer database was developed with staging
and outcome data on 100,869 lung cancer cases managed between 1990 and 2000. From
this, 67,725 met initial screening, 38,265 were clinically without metastases, and 28,371
had pathological staging (defined at thoracotomy). Further survival analyses in relation to
pN1 and pN2 subsets could be performed on only 2876 patients.
The authors analyzed survival by anatomic location (or “zone”) of involved nodes
(Table 2b), presence of skip metastases (Table 2c), and number of involved nodal stations
(Table 2a and Figure 5). “Zone analysis” was done after analyses by station failed to
identify significant differences. Zones were defined as peripheral (levels 12–14), hilar
(levels 10 and 11), upper (levels 1–4), aortopulmonary window (levels 5 and 6),
subcarinal (level 7), or lower (levels 8 and 9). Although significant differences were not
seen, right-sided tumors with single-zone N1 had median survival rates of 56 to 63 months
versus 34 to 37 months for single-zone N2. Left-sided tumors with single-zone peripheral
involvement had a median survival of 52 months versus 40 months for hilar and 39 to 44
months for mediastinal.
Patients with left upper-lobe tumors and skip metastases (N2 involvement in the
absence of N1) had improved survival (44 versus 24 months), whereas this difference was
not significant for right upper-lobe primaries (37 versus 28 months). Improved survival for
left upper-lobe/aortopulmonary window disease confirms previous reports and supports
surgical therapy for these “better” N2 patients. Sentinel node mapping may play a role in
the identification and further evaluation of “skip” metastases.
Survival analysis by number of involved lymph node zones was significant, with
three separate prognostic groups emerging: patients with single-zone N1 disease, multiple-
zone N1 or single-zone N2, and multiple-zone N2 (Figure 5). It is unfortunate that only
1992 cases had sufficient data for this analysis and that further exploration of these
prognostic nodal groups in conjunction with T stage could not be performed. Anatomic
location by zone did affect survival, with single-zone N2 faring worse than single-zone
N1, although the authors did not conclude this.
Increasingly smaller T1N0M0 lung cancers are being identified by computed
tomography screening, leading to the reevaluation of sublobar resection. To determine the
appropriateness of sublobar resection and accurate prognostication, meticulous intraop-
erative staging with dissection of level 10, 11, 12, 13, and 14 nodes will be required, as
eloquently demonstrated by Mr. P. Goldstraw (personal communication, Toronto Re-
fresher course, June 2006). Previously, most surgeons did not conduct such meticulous
staging; rather, they concentrated only on identifying N2 disease before proceeding with
resection. More recently, adjuvant chemotherapy has been shown to improve survival in
resected non-small cell lung cancer patients,3–5 and accurate lymph node staging is critical
for selection of patients most likely to benefit.
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Tumor, node, metastasis (TNM) staging has been the
basic classification for all solid tumors for decades. The use
of this system has assisted health care providers in the
selection of appropriate therapies for individual patients and
has defined appropriate populations for clinical research strat-
egies. Obvious issues with the current nodal station maps are
complexity (fewer than 5% of cases who met initial screening
criteria had sufficient nodal labeling/sampling for the final
analysis) and clinical heterogeneity within the N1, N2, and
N3 categories. Appropriate selection of radiation or surgery
for locally advanced patients cannot be made on the basis of
the current nodal descriptors.
The IASLC staging committee has validated the current
lung cancer lymph node staging descriptors and has proposed
a three-tiered zone system within the current N1 and N2
patient subsets for further evaluation. The authors did not
evaluate potential N3 subsets (contralateral mediastinal, uni-
lateral, or bilateral supraclavicular zones spring to mind), nor
did they address how future lung cancer databases should be
constructed to facilitate collaboration and research. Reconcil-
iation of the Naruke and ATS lymph node maps is being
addressed by the IASLC staging committee and should facil-
itate these efforts. The use of lymph node zones as suggested
in this paper may enhance data collection and analysis as a
simplification over the current 14-station system.
The IASLC is to be congratulated for tackling the huge
task of validating the current staging system and for embark-
ing on future collaboration for its revision. The staging
systems for lung cancer and, indeed, for all solid tumors
represent a work in progress. We look forward to the day
when accurate surgical and molecular staging will accurately
predict prognosis.
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